ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

COLL vs ANNX // EV/EBITDA & P/E VALUATION

Collegium Pharmaceutical Inc. (NASDAQ) VS. Annexon Inc. (NASDAQ) • 15-METRIC TALLY: COLL 4 — ANNX 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (COLL VS. ANNX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC COLL ANNX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 59.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 COLL /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 3.0x — — TIE /valuation <GO>
Free Cash Flow Yield — -24.53% — TIE /fcf-yield <GO>
Operating Margin 23.00% — — TIE /operating-margins <GO>
Net Profit Margin 8.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 23.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 1.27 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 COLL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 56.9 52.4 +4.48 COLL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 10.4x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $782.3M $760.2M $22.1M COLL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR COLL REV ANNX REV COLL GROSS % ANNX GROSS % COLL FCF ANNX FCF
FY 2025 $780.6M $0 59.3% — $327.6M -$186.5M
FY 2024 $631.4M $0 59.8% — $203.3M -$118.0M
FY 2023 $566.8M $0 — — $274.7M -$121.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
COLL // BETA —
ANNX // BETA —